A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

S. Sabry1,2,3,4, S. Vuillaume-Barrat1,2,5, E. Mintet1,2, M. Fasseu1,2, V. Valayannopoulos6, D. Héron7,8, N. Dorison8, C. Mignot7,8,9, N. Seta5,10, I. Chantret1,2, T. Dupré1,2,5 and S. E. H. Moore1,2*

Abstract

Background: Type I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins. A subgroup harbour mutations in genes necessary for the biosynthesis of the dolichol-linked oligosaccharide (DLO) precursor that is essential for protein N-glycosylation. Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins.

Results: Targeted sequencing of DNA revealed a splice site mutation in intron 5 and a non-sense mutation in exon 4 of the dehydrodolichol diphosphate synthase gene (DHDDS). Skin biopsy fibroblasts derived from the patient revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated DLO and N-glycans, and an increased ratio of [2-3H]mannose labeled glycoprotein to [2-3H]mannose labeled DLO. Predicted truncated DHDDS transcripts did not complement rer2-deficient yeast. SiRNA-mediated down-regulation of DHDDS in human hepatocellular carcinoma HepG2 cells largely mirrored the biochemical phenotype of cells from the patient. The patient also harboured the homozygous ALG6(F304S) variant, which does not cause CDG but has been reported to be more frequent in PMM2-CDG patients with severe/fatal disease than in those with moderate presentations. WES did not reveal other strong candidate causal genes.

Conclusions: We describe a patient presenting with severe multisystem disease associated with DHDDS deficiency. As retinitis pigmentosa is the only clinical sign in previously reported cases, this report broadens the spectrum of phenotypes associated with this condition.

Keywords: Protein N-glycosylation, Dolichol linked oligosaccharide, Retinitis pigmentosa, Endoplasmic reticulum

Background

Type I congenital disorders of glycosylation (CDG-I) are rare inborn errors in metabolism. A subgroup of CDG-I is caused by mutations in genes involved in the biosynthesis of the dolichol linked oligosaccharide (DLO) precursor required for protein N-glycosylation [1]. DLO is synthesized by a series of reactions, known as the dolichol cycle (Fig. 1), in which dolichol phosphate (DolP) is glycosylated with nucleotide sugars and DolP-sugars, to yield the mature DLO, Glc3Man9GlcNAc2-PP-dolichol [2, 3]. The sugar moiety of this donor is transferred from DLO onto nascent polypeptides by oligosaccharyltransferase (OST) while the byproduct of this reaction, dolichol-diphosphate (DolPP), is recycled by a complex process requiring DolPP phosphatase (DOLPP1) [2, 3]. A lack of mature DLO provokes protein hypoglycosylation. In addition to being recycled during protein N-glycosylation, DolP is synthesized as one of the end...
products of the mevalonate pathway (Fig. 1). In the first committed step of dolichol biosynthesis the enzyme cis-prenyltransferase (dehydrodolichol diphosphate synthase: DHDDS) that forms a complex with the Nogo-B receptor (NgBR) elongates a farnesyl diphosphate residue by addition of several isopentenyl moieties derived from isopentenyl diphosphate to yield dehydrodolichol diphosphate [4]. After dephosphorylation of dehydrodolichol diphosphate by poorly characterized enzymes, the resulting dehydrodolichol is reduced by polyprenolreductase (dehydrodolichol reductase or steroid 5α-reductase type 3: SDR5A3) to yield dolichol (Dol) [5] that is subsequently phosphorylated by dolichol kinase (DOLK) to yield DolP (Fig. 1). Dolichol kinase deficiency (DOLK-CDG: MIM612379) presents with hypoglycosylated serum glycoproteins, cardiac myopathy, muscular hypotonia and ichthyosiform dermatitis [6, 7]. Patients with mutations in polyprenolreductase (SDR5A3-CDG: MIM 613861) display hypoglycosylated serum glycoproteins, developmental delay, ataxia, visual impairment (optic nerve atrophy, retinal coloboma, cataract, glaucoma), liver dysfunction, coagulation abnormalities and ichthyosiform dermatitis [5, 8, 9]. NGBR-CDG patients present with scoliosis, neurological impairment, refractory epilepsy, ocular deficits, and visual impairment [10]. By contrast, DHDDS-CDG patients (MIM 613861) have so far not presented with hypoglycosylated serum glycoproteins and clinical signs are limited to retinitis pigmentosa [11, 12]. In the present report we describe biochemical findings in a fatal case of CDG-I in which mutations in DHDDS were found. Two mutations leading to 80 % reduction in DHDDS mRNA were identified. Skin biopsy fibroblasts revealed variable amounts of truncated DLO and N-glycans, 35 % residual DHDDS activity, reduced DolP, and down-regulation of DHDDS in HepG2 cells leads to truncated DLO. While whole exome sequencing confirmed the presence of the DHDDS mutations, it did not reveal strong alternative candidate genes involved in protein N-glycosylation.

Methods

Patient

The boy was the first child of non-consanguineous parents. During pregnancy intra-uterine growth retardation and decreased fetal movements were noted. He was born at 37 weeks of gestation with a weight of 2090 g (−3.25 SD), a length of 42 cm (−4 SD), an occipitofrontal circumference of 32 cm (−2 SD) and Apgar score 10/10. He had two episodes of severe bradycardia during his first day of life and was transferred to an intensive care unit. At clinical examination, the patient had axial hypotonia, peripheral hypertonia, enlarged liver, micropenis and cryptorchidism. He had a transient increase of serum transaminases, renal failure and developed epilepsy. Liver sonography revealed mild dilatation of the biliary duct. During his short life, the boy made little psychomotor acquisitions, had no eye contact, poor sucking with frequent regurgitations and failure to thrive. At 2 months, the fundus oculi displayed pale papillae and the electroretinogram showed no response to any type of stimulation. Brainstem evoked auditory potentials showed sensorineural deafness with an auditory threshold of 90 dB (right ear) and 100 dB (left ear). The patient died at 8 months during a status epilepticus.
Reagents
[2-3H]mannose (21.5 Ci/mmol), [6-3H]glucosamine (37.7 Ci/mmol), [14C]-isopentyl diphosphate (56.6 mCi/ mmol), GDP-[14C]mannose (262 mCi/mmol), UDP-[14C]glucose (348 mCi/mmol), UDP-[3H]GlcNAc (37 Ci/ mmol), ULTIMA GOLD and En3Hance were from Perkin Life Sciences, Fr. RPMI 1640 medium, penicillin-
 streptomycin (PS), fetal calf serum (FCS), OPTIMEM, stealth RNAi, Lipofectamine RNAiMAX and the BCA™ Protein assay kit were from Thermo Scientific, Cergy Pon
toise, FR. Peptide N-glycanase, bacitracin, Dowex resins and protease inhibitors were obtained from SIGMA. The tripeptide acetyl-Asn-Tyr-Thr-NH2 (Ac-NYT-NH2) was purchased from Neosystem (Strasbourg, Fr.). TLC plates were obtained from Merck (Darmstadt, Germany).

Cell culture
Skin biopsy fibroblasts [13] and HepG2 cells [14] were cultivated as previously described.

Sequencing
For gene studies, signed informed consent protocols were obtained from the parents. Ethics approval was from the Comité de Protection des Personnes d’Île-de-France 2 (CPP IDF2). Targeted genomic Sanger sequencing of several genes encoding proteins required for DLO biosynthesis [PMM2 (NM_000303), ALG6 (NM_013339), DPM1/2/3 (NM_003859, NM_003863, NM_153741), MP DU1 (NM_004870), ALG2 (NM_033087), ALG7 (NM_ 001382), ALG1 (NM_019109), ALG13/14 (NM018466, NM_144988), ALG11 (NM_001004127)] and dolichol biosynthesis (DHDDS, NM_020438) was performed on DNA from fibroblasts derived from the patient. Primer sequences are available upon request. DNA from the parents was extracted from whole blood. Informed consent was obtained from the parents. WES libraries were prepared from 3 g of genomic DNA, which was sheared by ultrasonication using a Covaris S220 Ultraso
dicator. The 51 Mb SureSelect Human All Exon kit V5 (Agilent technologies) was used for exome capture, and sequencing of WES libraries was carried out on a HiSeq2500 sequencer (Illumina) [15]. The mean coverage depth was 244.51× ((98.22 > 30×; 99.74 > 15× and 99.93 > 5×). After de-multiplexing, sequences were aligned to the reference human genome hg19 using the Burrows-Wheeler Aligner. Downstream processing was carried out with the Genome Analysis Toolkit (GATK), SAMTools, and Picard, following documented best practices (https://www.broadinstitute.org/gatk/guide/ bp_step.php). Variant calls were made with the GATK Unified Genotyper. The annotation process was based on the ensembl database (75), dbsnp (135) EVS (ESP6500SI-V2), 1000 genome (2011 05 21) and EXAC (0.3). Variants were annotated and analysed using the Polyweb software interface designed by the Bioinformatics platform of University Paris Descartes and Imagine Institute [16].

SiRNA-mediated down-regulation of DHDDS expression in HepG2 cells
HepG2 cells were transiently transfected with 25 pmol siRNA as previously described [14]. Three DHDDS-
targeting sense sequences (1; AACAAGUGCAAGCGCCAGGACCC, 2; CCAACCGCGUCUGUUGCAGAU, 3; CCGCUUCUCUCAUGUGCCAGU) and a medium GC non-targetting control sequence were used. Cells were harvested 2, 4 and 6 days after transfection.

RNA extraction, reverse transcriptase and reverse QPCR
RNA was extracted from fibroblasts or HepG2 cells according to the manufacturer’s instructions (RNeasy Plus Mini Kit, Qiagen). Reverse transcriptase reactions were performed with 1 µg RNA using the Verso cDNA synthesis kit (Thermo Scientific). RT PCR from cDNA exon 3 to 7 of the DHDDS gene (primer sequences: 3SRT cactcacagctctcaacaagc and 7RRT cggttgttagaggtc
tctt) was performed to confirm the splicing mutation. QPCR was performed using the Absolute Blue QPCR SYBER Green Mix Plus ROX vial (Thermo Scientific) in a Roche Light Cycler 480. Primers for QPCR of DHDDS and the HMBS housekeeping gene were purchased from Qiagen. Primer sequences for the S14 housekeeping gene are as follows: S14 Sense: TCACCTCGGAAGATACCATTTTG, S14 Reverse: CCGATTCTGTACTTACAGGAC.

Metabolic radiolabelling of cells
Confluent 125 cm2 flasks of fibroblasts were metabolic
ally radiolabelled for 30 min in glucose free RPMI 1640 medium supplemented with 0.5 mM glucose and 2 % dialysed foetal calf serum with 100 µCi [2-3H]mannose [17]. SiRNA-treated HepG2 cells were radiolabeled for 30 min in 500 µL/well glucose-free RPMI 1640 medium supplemented with 1 mM glucose, 2 mM fucose, 2 % dialyzed FCS and 50 µCi [2-3H]mannose [14].

Characterisation of dolichol linked oligosaccharides and N-glycans
The following experimental procedures are described in detail elsewhere [13]. Briefly, after washing with ice-cold PBS, cells were scraped into 1 volume 100 mM Tris–
HCl (pH 7.4) containing 4 mM MgCl2. Two volumes of methanol followed by 3 volumes of chloroform were added to the aqueous cell suspension. After vigorous shaking, the CHCl3 and MeOH/H2O phases were separated by centrifugation and removed. The interface pellet was extracted twice with 3 ml CHCl3:CH3OH:H2O
(CMW, 10:10:3). The CHCl₃ phase and CMW fractions contain DLOs with small and large glycan chains, respectively. Both fractions were dried under vacuum and subjected to acid hydrolysis in 20 mM HCl. After desalting on combined Dowex 1-X2 (acetate form)/Dowex 50-X2 (H⁺ form) resins the released oligosaccharides were dried under vacuum and, after pooling fractions derived from the two organic phases described above, were examined by thin layer chromatography (TLC). N-linked oligosaccharides (NLOs) were released from the interface protein pellets with PNGase F as previously described [18].

Dolichol-P-mannose synthase and DHDDS assays

Total HepG2 and fibroblast membranes were prepared as previously described [17]. Dolichol-P-mannose synthase (DPMS) was assayed as reported previously in either the presence or absence of DolP [18]. The same membranes were used to assay DHDDS in either the presence or absence of farnesyl diphosphate (FPP) [19]. For the latter assay, the 50 µL reactions were stopped by the addition of 500 µL CHCl₃/MeOH (2:1) before transferring the mixtures to 15 mL tubes containing 3.5 mLs CHCl₃/MeOH (2:1). Two phases were then obtained after addition of 800 µL 4 mM MgCl₂. The upper phase was removed and discarded whereas the lower phase was washed with 2 x 2 mLs 4 mM MgCl₂/MeOH (1:1). Radioactivity in the lower phase was then assayed by scintillation counting.

Detection of endogenous Dol-P

Endogenous Dol-P levels were assayed in sealed ER vesicles as previously described [20]. A sample of sealed ER-vesicles (equivalent to 40 µg protein) was incubated in 50 mM Tris–HCl (pH 7.5) containing: 250 mM sucrose, bacitracin (400 µg/mL), acceptor peptide (35 µM), AMP (4 mM) and CaCl₂ and MgCl₂ (5 mM) in a total volume 30 µL. The reaction mixture was incubated for 10 min at 37 °C. GDP-[¹⁴C]Man (3 µM) was added and the mixture was incubated for 2 min at 37 °C. After solvent extraction, radioactivity was assayed in the organic phase by scintillation counting. The assay was also performed in the absence of the synthetic acceptor peptide as a negative control. Blanks, without sealed ER-vesicles, were made for each condition.

Thin layer chromatography

Desalted DLOs and NLOs were resolved on silica-coated plastic TLC plates developed for 18 h in a mobile phase of propan-1-ol: acetic acid: water (3:3:2). After drying the plates, radioactive components were visualized by fluorography after spraying with En³Hance.

Protein expression in skin biopsy fibroblasts and HepG2 cells

Proteins were extracted using a lysis buffer containing 20 mM Tris–HCl, 150 mM NaCl, 1 % TX-100, 1 % protease and phosphatase inhibitors, and subjected to SDS-PAGE using NuPage 4–12 % Bis-Tris gels (Fisher-Thermo Scientific). The following primary antibodies were used: anti- ICAM-1 sc-107 (Santa Cruz), anti-PDI (Cell Signaling), anti-ATF-6α (F-7) sc-166659 (Santa Cruz), anti-p-PERK (Thr 981) sc-32577 (Santa Cruz), anti-NgBR IMG-5342-A (Imgenex), anti-Calnexin 610823BD (BD Transduction Laboratories), anti-GRP75 BiP ab-21685 (Abcam), anti-Actin (I-19) sc-1616 (Santa Cruz).

Complementation of RER2-deficient S. cerevisiae with wild-type and mutant human DHDDS forms

True clone DHDDS (SC321506, NM-205861; 1) was mutated with QuickChange site-directed mutagenesis kit (Stratagene) in K42E and W64X and then subcloned into the yeast p416TEF plasmid [21]. Wt RER2 was obtained by cloning PCR from yeast DNA in plasmid pCR2.1 (TA cloning) and then subcloned into p416TEF. The mutated DHDDS was tested in the RER2-TET-off strain cultivated in the presence of 0.3 µM doxycycline. Yeast strains in which the RER2 (rer2DR), ALG14 (alg14DR), ALG13 (alg13DR) and ALG7 (alg7DR) genes are under the control of the TET repressor were cultivated, alongside a parental strain, in the presence of increasing concentrations of doxycycline for two overnight passages in order to induce gene down regulation. During the second passage, culture growth was measured by turbidometry, and inhibition of growth with respect to that seen in the absence of doxycycline was calculated. Subsequent to cultivation of alg14DR and rer2DR cells in either the absence or presence of 1.0 and 0.3 µg/mL doxycycline, respectively, as described above, cell extracts [22] were submitted to SDS-PAGE and Western Blot using an antibody directed to carboxypeptidase Y (CPY).

Results

Glycosylation profile of plasma glycoproteins

Figure 2a shows Western blotting of the plasma glycoproteins a1-antitrypsin (AAT), transferrin (TF), haptoglobin (HAPTO) and orosomucoid (OROSO) derived from the patient (P), a patient diagnosed with PMM2-CGD and a normal subject (N). The patient manifests additional AAT, HAPTO and OROSO glycoforms of inferior molecular weight reflecting hypoglycosylation [23].

Analysis of protein N-glycosylation in patient fibroblasts

Metabolic radiolabelling of skin biopsy fibroblasts with [2-³H]mannose revealed that cells from the patient
generated elevated levels of truncated DLO possessing oligosaccharides bearing 5–9 residues of mannose as well as fully mannosylated species containing 1–2 residues of glucose (Fig. 2b). N-glycan (NLO) analysis also revealed truncated species bearing 4–8 residues of mannose. The experiment showed in Fig. 2b is representative of several radiolabelling experiments: in some experiments the truncated species were more apparent and in others less so and, more generally, this phenotype gradually became less apparent as a function of cell passage number. As the metabolic radiolabelling procedure is carried out in the presence of low glucose concentrations, which is known to favour the appearance of truncated DLO, we investigated the role of the extracellular glucose concentration on the appearance of truncated DLO in two cell populations derived from separate skin biopsies obtained from the patient. It was noted that both cell populations behaved similarly and that when radiolabelling was performed in the presence of 2 mM glucose (instead of the usual 0.5 mM glucose) truncated DLO were still observed (results not shown). To conclude, oligosaccharide profiles did not point to an obvious block in the dolichol cycle. In addition to truncated DLO, it was noticed that the ratio of the quantity of radioactivity associated with NLO to that associated with DLO was high in cells from the patient compared to control cells or those from other patients with CDG-I (Fig. 2c).

Mutations found in DHDDS gene
Routine targeted Sanger sequencing of several genes encoding proteins required for DLO biosynthesis (PMM2, ALG6, ALG7, ALG13/14, ALG1, ALG2, DPM1/2/3, DOLK MPDU1, and ALG11) did not reveal potential disease causing variants. The patient was found to be homozygous for the c.911 T > C (p.F304S) ALG6 variant (see Fig. 1b) that occurs in about one third of the population and does not cause CDG, but as will be discussed later, has been reported to be associated with severe disease signs in patients whose glycosylation pathway is otherwise compromised. While sequencing genes required for dolichol biosynthesis, two mutations in the DHDDS gene were found in DNA from the patient (Fig. 3a). After sequencing DNA from the parents it was found that the father harboured a nonsense mutation c.192G > A (p.W64X) in exon 4 (Fig. 3a; upper panel), and the mother possessed a splicing mutation (c.441-24A > G) in intron 5 (Fig. 3a; lower panel) that creates a cryptic donor splice site (with score of 0.99 rather than 0.65 for the normal exon 6 donor site) leading to: i) loss of exon 6, ii) a 63 base insertion into intron 5 (Fig. 3b), iii) a premature stop: c.440_543del102ins63 (p.C148EfsX11).

Complementation of RER2-deficient S. cerevisiae with wild-type and mutant human DHDDS forms
Both mutations potentially lead to the generation of severely truncated proteins devoid of the isopentenyl pyrophosphate-binding domain (Fig. 3c). A yeast complementation strategy was used to test the functionality of the truncated DHDDS(W64X) protein. In the yeast S. cerevisiae, the DHDDS gene is encoded by RER2 and the rer2Δ strain is not viable. RER2 function in S. cerevisiae can be evaluated using the TET-off system in which the RER2 gene is invalidated upon addition of doxycycline to the culture medium as shown in Fig. 4a. The data shows that down-regulation of RER2 causes striking growth retardation that is more pronounced than that
observed when genes required for early steps in DLO biosynthesis (ALG7, ALG13 and ALG14) are downregulated in the same way. As shown in Fig. 4b, this growth reduction is accompanied by the appearance of hypoglycosylated carboxypeptidase Y (CPY), which is a well-known marker for N-glycosylation in *S. cerevisiae*.

The functionality of the DHDDS(W64X) variant was tested in the RER2-TET-off strain cultivated in the presence of 0.3 μM doxycycline. Under these conditions, as shown in Fig. 4b, both growth and CPY N-glycosylation were restored when the RER2-TET-off strain was transduced with either wild type RER2 or wild type human DHDDS, but not with plasmids containing either DHDDS(W64X) or the DHDDS(K42E) variant that is associated with retinitis pigmentosa.

**Reduced DHDDS gene expression and biological activity in cells from the patient**

The DNA sequencing data suggests that cells from the patient should manifest reduced DHDDS expression. The intronic mutation inherited from the mother does not exclude utilization of the normal splice site so some full length DHDDS mRNA is expected in cells from the patient. Full length DHDDS mRNA was quantitated in
the skin biopsy fibroblasts from the patient and a normal subject, and, as shown in Fig. 5a, the patient possessed only 20–25 % normal DHDDS mRNA level. DHDDS activity in crude microsomal preparations derived from cells from the patient was found to be 35 % of that found in those of cells from normal subjects (Fig. 5b and c). By contrast, dolichol-P-mannose synthase (DPMS) activity was found to be similar in the two microsome preparations (Fig. 5d).

**Reduced dolichol-phosphate levels in sealed microsomes derived from cells of the patient**

The DolP pool available for DLO biosynthesis was estimated in either the absence or presence of a synthetic acceptor peptide (Acetyl-Asn-Tyr-Thr-NH₂: NYT) that is known to provoke DolP recycling in sealed microsomes [20]. Addition of NYT to sealed microsomes causes DLO to be discharged: yielding glycopeptide and DolPP. DolPP phosphatase (DOLPP1, see Fig. 1) converts DolPP into DolP, which can then be quantitated as Dol-P-[14C]Man after addition of GDP-[14C]Man and by allowing DPMS action (that occurs at the same levels in microsomes derived from cells of the patient and control subject, Fig. 5d). Bacitracin complexes DolPP and incubations in the absence or presence of this antibiotic allow estimations of both DolPP-, and DolP-dependent Dol-P-[14C]Man production. As shown in Fig. 5e, bacitracin inhibits Dol-P-[14C]Man production even in the absence of NYT indicating Dol-PP production via the presence of endogenous substrates for OST. Dol-P-[14C]Man generation in the presence of bacitracin reveals a pre-existing DolP pool that, in microsomes from the patient, appears to be reduced by ~67 % compared to the control. Finally, it can be seen that microsomes from the patient also demonstrate lower NYT-provoked Dol-P-[14C]Man synthesis. The ensemble of these data demonstrates a deficit in the quantity of DolP available for synthesis of Dol-P-[14C]Man in the patient’s cells. In order to evaluate the consequences of the reduced DolP levels in the patient’s cells, the glycosylation status of ICAM was examined. Hypoglycosylated ICAM is rapidly degraded and this has been shown to yield low steady state levels of this protein in type I CDG cells [24]. Data presented in Fig. 5f indicate that although the ICAM level is low in the patient’s cells, this level is within the range of ICAM expression in the control cell lines. Protein hypoglycosylation in type I CDG may lead to increases in protein misfolding, ER stress and initiation of the Unfolded Protein Response (UPR) [25]. However, the level of the ER stress marker calnexin (CNX) is within the range displayed by the control cells. Interestingly, there is an inverse correlation between ICAM and CNX expression in both control and patient cells. The reason for the variable ICAM expression even within the control cell population is unknown but could be due to the different growth characteristics or passage number of the different cell lines. ATF46α is a UPR signaling protein [26], and when unfolded proteins accumulate in the ER the expression of full length ATF46α (Fig. 4f, ER; 90 kD) is increased as well as its proteolytic cleavage to generate the 57 kD...
The ER form of ATF46α is expressed at a higher level in the patient’s cells than in both control cells, and those from other CDG-I patients. However, this increased expression was not accompanied by increased proteolytic cleavage to generate the active nuclear form of the protein (Fig. 5f).

Knock-down of DHDDS expression in HepG2 cells
The data presented above demonstrate the presence of mutations in the DHDDS gene that lead to: 1) reduced DHDDS mRNA levels, 2) reduced DHDDS activity, 3) reduced DolP levels, and 4) small but significant changes in DLO/N-glycan profiles in metabolically radiolabeled
fibroblasts derived from the patient. In order to determine whether or not reduced DHDDS expression could lead to the changes in early steps of the N-glycosylation pathway that were noted in the cells from the patient, human hepatocellular carcinoma HepG2 cells were transfected with siRNA duplexes targeting DHDDS. As shown in Fig. 6a, DHDDS mRNA expression was decreased by three DHDDS-targetting duplexes (1-3) compared to the non-targetting duplex (nt), and siRNA(1) was the most efficient at reducing DHDDS expression. SiRNA(2) provoked an increase in non adherent cells (not shown), a reduction in protein associated with adherent cells (Fig. 6b), and reduced protein synthesis as measured by [14C]leucine incorporation into precipitable cellular proteins (Fig. 6c). Because siRNA(1) provoked more effective DHDDS mRNA down-regulation than siRNA(3) and siRNA(2) manifested toxicity not apparent with the other duplexes, the former duplex was selected for the following experiments. In order to assay DHDDS activity in

Fig. 6 Down-regulation of DHDDS expression in HepG2 cells. HepG2 cells were transfected with three siRNA targeting DHDDS or a control non-targetting siRNA (nt) and were harvested 4 days later. a Cellular mRNA was extracted and DHDDS cDNA was quantitated by qRT-PCR. b Total adherent cell protein was assayed. c Cells were radiolabeled with [14C]leucine for 30 min, and radioactivity recorded in precipitated cellular proteins was calculated per mg protein and these values were expressed as a percentage of that found in cells transfected with the control non-targetting siRNA. d DHDDS activity was measured in the three cell populations. e HepG2 cells were mock transfected (None), or transfected with either the control non-targetting siRNA (nt) or siRNA(1) targeting DHDDS, and at 2, 4 and 6 days post transfection the cells were metabolically radiolabeled with [2,3H]mannose. Radioactivity associated with DLO (upper panel) and glycoproteins (NLO, middle panel) was measured as described in the legend to Fig. 2c, and the ratio of incorporation of radioactivity into NLO to that into DLO is shown in the lower panel. f Oligosaccharides released from DLO were resolved by TLC and visualized by fluorography. Regions corresponding to the migration positions of the indicated oligosaccharides were eluted from the plate and assayed by scintillation counting. The abbreviations are as follows: G3-1; Glc3Man9GlcNAc2, M9-2; Man9GlcNAc, Sabry et al. Orphanet Journal of Rare Diseases (2016) 11:84
Poly-ADP-ribosyltransferases are 3 results not 2 including ALG8, ALG9, –α ot cause CDG, the possibility –25 % DHDDS mRNA expression + not be excluded, but it was lically radiolabeled with [2-\text{H}]mannose as described for Fig. 2b. As shown in Fig. 6e, transfection of the cells with the DHDDS-targetting siRNA(1) reduced radiolabel incorporation into DLO (upper panel) without strikingly affecting the quantity of radioactivity associated with N-glycans (middle panel). The resulting high ratio of [2-\text{H}]DLO/[2-\text{H}]N-glycan (lower panel) in the DHDDS-down-regulated cells is similar with the fibroblasts derived from the patient (Fig. 2c). TLC examination of the DLO structures generated under the different conditions demonstrates the presence of various truncated DLO associated with DHDDS down-regulation at days 4 and 6 post-transfection (Fig. 6f). Finally, down-regulation of DHDDS in HepG2 cells did not lead to changes in the expression of ICAM, calnexin and ATF46 (results not shown). To summarize, as was noted in fibroblasts from the patient, DHDDS down-regulation in HepG2 cells provokes the appearance of truncated DLO and an elevated [\text{3}^\text{H}]DLO/[\text{3}^\text{H}]N-glycan ratio.

Whole exome sequencing
The clinical phenotype of the patient reported here resembles that of other CDG-I patients and contrasts with the retinitis pigmentosa phenotype of the first reported DHDDS-deficient patients. This different phenotype could be explained by the presence of a mutation in another gene that regulates N-glycosylation, or the association of DHDDS mutations with mutations in genes that regulate N-glycosylation. Sanger sequencing revealed the patient to be homozygous for the c.911 T > C (p.F304S) ALG6 variant (see Fig. 1b) that does not cause CDG, but is associated with severe disease signs in patients who have mutations in other genes of the N-glycosylation pathway. In order to look for other potentially disease causing or disease modifying variants, whole exome capture and next-generation sequencing (WES) on an Illumina platform was performed on DNA from fibroblasts of the patient. After filtering out variants occurring at >1 % in human population data banks (the c.911 T > C (p.F304S) ALG6 variant was detected but filtered out because it occurs at a frequency of 20–30 %), and selecting those associated with glycosylation or dolichol metabolism pathways, two genes were found with two variants: DHDDS and TNKS1 (Tables 1 and 2). TNKS1 (Tankyrase, TRF1-Interacting Ankyrin-Related ADP-Ribose Polymerase) functions include NAD+–dependent ADP-ribosyltransferase activity. Poly-ADP-ribosyltransferases are involved in various processes such as Wnt signaling, telomere length maintenance and vesicle trafficking [27]. In certain situations, the chromosomal location of the TNKS1 gene (8p23.1) is linked to a form of monogenic diabetes [28]. Despite being lean and in other respects normal, TNKS1-deficient mice display hyperphagia and altered fatty acid metabolism without liver steatosis [28]. WES also identified several heterozygous variants in genes of the N-glycosylation pathway (Table 2) including ALG8, ALG9, DDOST, MPDU1, ALG6, and STT3A. Even though single mutations in these genes do not cause CDG, the possibility that reduced activity/expression of the proteins that they encode could amplify the phenotype caused by reduced DHDDS expression cannot be excluded. The possibility of further CDG gene variants hiding in an intron or poorly covered region during WES cannot be excluded, but it was found that for the 26 genes presently known to underlie CDG, WES coverage was at least 30×.

Discussion
This case is of considerable interest because other patients so far described with mutations in the DHDDS gene present with a mild clinical picture restricted to retinitis pigmentosa [11, 12, 29]. The present patient showed a fatal clinical syndrome accompanied with hypoglycosylated serum glycoproteins and truncated DLO species, pointing to CDG-I. Two mutations in DHDDS leading to 20–25 % DHDDS mRNA expression and 35 % residual DHDDS activity were found. In accordance with these data microsomes derived from the patient's cells revealed low levels of DolP. As our studies progressed, and the passage number of the fibroblasts increased, we noted a gradual disappearance of the glycosylation phenotype. Although it is not clear why this should occur, it is possible that as the cells become less metabolically active their glycosylation requirements are reduced and there is less strain on the dolichol cycle. The disappearance of the glycosylation phenotype, and the fatal outcome in this case, made it no longer feasible to try to normalize either the abnormal DLO profile or [2-\text{H}]mannose incorporation into DLO by transfecting cells from the patient with wild-type hDHDDS. In an alternative approach to investigate the origin of the biochemical phenotype, DHDDS expression was down regulated in HepG2 cells. To date, there have been no attempts to knockdown DHDDS expression in mice or mammalian cells in vivo. It was noted that whereas DHDDS-down regulation in HepG2 cells provoked an 80–90 % reduction in DHDDS RNA, only a 50 % reduction in DHDDS activity could be detected. This result was surprising and raises the possibility of an alternative mechanism for dolichol biosynthesis that is relatively more important in HepG2 cells than in fibroblasts. Alternative dolichol biosynthetic
routes postulated previously [30, 31] remain controversial [32]. Nevertheless, such a route might explain the shorter dolichol chain lengths that have been observed in NGBR- and DHDDS-deficient patients [10, 33]. Here we demonstrate that siRNA-mediated knockdown of DHDDS did not reduce the incorporation of [2-3H]mannose into glycoproteins, but did reduce strikingly the incorporation of [2-3H]mannose into DLO, and provoked a transient increase in the proportion of truncated DLO species (Man$_{6-8}$GlcNAc$_2$-PP-dolichol).

One explanation for the occurrence of truncated DLO in DHDDS-deficient cells with reduced DolP is that the synthesis of Dol-P-Man and Dol-P-Glc are more adversely affected than Dol-PP-GlcNAc. This would lead to a DLO profile similar to that seen in MPDU1-CDG where the ability of these two precursors to contribute to DLO elongation is compromised [34]. Alternatively, the slightly shorter dolichol chains that have been shown to occur in previously described DHDDS- and NGBR-deficient patients may also hinder Dol-P-Man and Dol-P-Glc utilization. The mechanism underlying the paradoxical apparent increase in incorporation of radioactivity into N-glycans with respect to that incorporated into DLO is also not clear. One explanation might be that the reduced DolP pool size could lead to a higher specific activity of the radioactive DPMan DLO pools compared to control cells. Accordingly, assuming that protein synthesis rates are similar and that the DLO pools are not limiting in control and DHDDS-deficient cells then a higher incorporation of radioactivity into N-glycans might be expected. An alternative hypothesis for the inability of DHDDS down regulation to inhibit the incorporation of radioactivity into N-glycans despite reducing radioactivity associated with DLO is that the DLO pool required for protein glycosylation is a sub pool of total DLO, and that this sub pool is less dependent upon DHDDS than the remaining DLO. To summarise, in both cells from the patient and DHDDS-deficient HepG2 cells, changes in the incorporation of [2-3H]mannose into DLO and N-glycans along with changes in the DLO profiles were detected. Therefore it is concluded that the biochemical phenotype of cells from the patient is compatible with reduced DHDDS expression.

The previously described patients with mutations in the DHDDS gene that present only with retinitis pigmentosa [11, 12, 29], do not present with serum glycoprotein hypoglycosylation. In these patients serum and urine dolichols are abnormal [33]. Serum and urine samples from our patient were not available. The DHDDS ortholog, RER2, is an essential gene in yeast,

### Table 1: Whole exome sequence filtering

| SNVs$^a$ | Variations | Genes |
|----------|------------|-------|
| All variants | 9061 | 6301 |
| Unknown or known variants <1% (dbSNP132/1 K genome/EVS ExAC) and in-house database filtering (929)$^b$ | 785 | 861 |
| Glycosylation genes | 19 | 19 |
| Dolichol related genes | 3 | 3 |
| Gene(s) with two mutated alleles | 2 | 2 |

$^a$SNVs single nucleotide variants
$^b$dbSNP132: http://www.ncbi.nlm.nih.gov/SNP/
1 K genome; 1000 genomes (http://www.1000genomes.org/), EVS, Exome Variant Server (http://evs.gs.washington.edu/EVS/), ExAC, http://exac.broadinstitute.org/, in-house database filtering; variant excluded if already seen at the homozygous state in 929 exomes performed in the platform

### Table 2: Glycosylation or dolichol related genes with mutated alleles

| Gene | SNP$^a$ | Type of mutation$^b$ | Frequency data if already described$^c$ |
|------|---------|----------------------|---------------------------------------|
| DHDDS | c.192G > A (p.W64X) | Stop | - |
|      | c.441-24A > G (p.C148FfsX11) | Intron (splice) | ExAC: 0.0001663 |
| TNKS | c.1945G > A (p.D649N) | Missense (Polyphen pathogen, SIFT benign) | - |
|      | c.899-16362A > T | Intron/ncRNA | - |
| ALG8 | c.1068C > G (p.P356=) | Exon synonymous | - |
| ALG9 | c.37-77G > A | Intron | - |
| DDOST | c.679A > G (p.I227V) | Missense (Polyphen and SIFT benign) | ExAC: 0.0004444 |
| MPDU1 | c.393C > T, p.V131 = (rs79286384) | Exon synonymous | Av. he: 0.004 ExAC: 0.0007853 |
| ALG6 | c.987 + 43 T > C (rs181709997) | Intron | Av. he: 0.003 ExAC: 0.003458 |
| STT3A | c.88 + 131 T > C (rs191172467) | Intron | Av. he: 0.001+/−0.024 ExAC: no data |

$^a$Genomic positions are on UCSC genome Browser (hg19)
$^b$Polyphen: http://genetics.bwh.harvard.edu/pph/, SIFT: http://sift.jcvi.org/
$^c$Av. he: average heterozygosity (source dbSNP) or allele frequency ExAC
and DOLK-CDG, SRD5A3-CDG and NGBR-CDG patients, who have mutations in other genes required for the de novo biosynthesis of dolichol, present with moderate to severe multisystemic manifestations [5, 10, 35]. Several explanations are possible for the differences in these DHDDS-CDG phenotypes.

First, the K42E mutation, associated with isolated retinitis pigmentosa, is perhaps not particularly damaging. Functional glycosylation studies and DHDDS assays have not been performed in fibroblasts from these patients, so no comparison can be made with the findings in cells from the present patient. Nevertheless, we report here that wild-type hDHDDS, but not hDHDDS(K42E), is able to normalise both impaired growth and carboxypeptidase Y hypoglycosylation in RER2-deficient S. cerevisiae. Interestingly, we present data indicating that doxycycline-induced knockdown of other essential yeast glycosylation genes (ALG7, ALG13 and ALG14) has much less impact on S. cerevisiae growth than down-regulation of RER2. This observation suggests that the RER2-dependent dolichol pool is required for important cellular functions other than protein N-glycosylation, or that RER2 itself has a role in yeast homeostasis independent of its role in dolichol production. Although the hDHDDS(K42E) variant is unable to complement growth or N-glycosylation defects in S. cerevisiae, its ability to support N-glycosylation in mammalian/human cells maybe quite different due to the fact that efficient dolichol biosynthesis by the hDHDDS-encoded protein requires the hNGBR-encoded protein [4, 10, 36]: a complex between hDHDDS(K42E) and the yeast NgBR ortholog (nus1) may not be as productive as that comprising both human proteins. More recently, however, it has been demonstrated that membranes derived from nus1Δrer2Δyeast complemented with hDHDDS(K42E) and wild-type hNGBR display about 50 % the activity of those derived from the same strain complemented with wild-type hDHDDS and hNgBR [10]. Therefore hDHDDS(K42E) does not support efficient DHDDS activity.

Second, the reduced DHDDS activity caused by the K42E variant may not be too serious for cells (apart from those in the retina). However, reduced expression of the DHDDS protein may be far more serious. DHDDS knockdown in fertilized zebrafish eggs caused primarily retinal photoreceptor degeneration, but, depending on the degree of knockdown, provoked other phenotypic changes that suggest roles for DHDDS are not restricted to retinal photoreceptor maintenance in this organism. Accordingly, reduced DHDDS expression may be more damaging than normal expression of the inactive hDHDDS(K42E) variant, potentially suggesting that DHDDS has important functions that are independent of its DHDDS activity. Nevertheless, an understanding of the impact of DHDDS knockdown on mammalian physiology will have to await the generation of mice models. The DHDDS protein forms a complex with the NgBR to form the fully active dehydrodolichol diphosphate synthase activity. NgBR also forms a complex of unknown function with the Nogo-B protein, and a complex with the Niemann-Pick C2 protein (NPC2) that is known to regulate cholesterol metabolism. NgBR knockout is embryonically lethal in mice and NgBR-deficient cells, derived from either patients with mutations in NgBR or mouse embryonic fibroblasts derived from conditional NgBR−/− mice, display 10-17 % residual DHDDS activity, reduced ICAM expression and about 50 % reduction in [2-3H]mannose incorporation into glycoproteins [10]. Accordingly, one of the consequences of reduced DHDDS protein expression, that is independent of reduced enzyme activity, might be an excess of “free” NgBR that could deregulate cholesterol metabolism or pathways that depend on the Nogo-B protein.

Third, Sanger sequencing revealed that the patient was homozygous for the ALG6(F304S) variant, which is more frequent in PMM2-CDG patients with severe disease than in those with moderate symptoms [37]. The ALG6(F304S) variant is not as efficient at complementing ALG6-deficient yeast as the wild type allele [38], but is not thought to cause CDG because it occurs in 27–33 % of the population, and 4–6 % of the population are homozygous for this variant [37, 39, 40]. DLO analyses in fibroblasts derived from the patient did reveal accumulations of Man5GlcNAc2−PP-dolichol above control levels (Fig. 2b), but other DLO species accumulated to a greater extent, and this DLO profile is not indicative of ALG6-CDG. WES of our patient revealed two variants in the tankyrase 1 (TNKS1) gene along with heterozygous variants in other genes (ALG6, ALG8, ALG9, DDOST, MPDU1, and STT3A) required for N-glycosylation. A role for these variants in the fatal outcome of this disease cannot be excluded.

**Conclusions**

We describe a patient presenting with severe multisystem disease associated with DHDDS deficiency. As retinitis pigmentosa is the only clinical sign in previously reported cases of DHDDS deficiency our data broaden its phenotypic spectrum. This case adds to those in which the ALG6(F304S) variant is associated with a severe/fatal disease presentation.

**Abbreviations**

CDG, congenital disorders of glycosylation; DHDDS, dehydrodolichol diphosphate synthase; DLO, dolichol linked oligosaccharide; DolP, dolichol phosphate; DolPP, dolichol diphosphate; NgBR, Nogo-B receptor; OST, oligosaccharyltransferase; siRNA, short interfering RNA.
Acknowledgements
Olivier Albieux and Marc Bras from, respectively, the Genomic and Bioinformatic Platforms, INSERM UMR 1163, Imagine Institute, Paris, France, are thanked for performing the WES analyses.

Funding
This work was partially supported by grant ERA4Net-135 of the ERA-Net for Research Programs on Rare Diseases Joint Transnational Call 2011 (EURO-CDG), the European Union FP6-Coordination Action EUROCANCET (LSHM-CT-2005-512131), and institutional funding from Institut National de la Sante et de la Recherche Medicale (INSERM). The whole exome study was funded by the association Connaître les Syndromes Cérébelleux (CCCL). The funding bodies played no role in the design, execution and reporting of this study.

Availability of data and supporting material
Not applicable.

Authors’ contributions
DH, ND and CM performed the clinical evaluations and provided patient care. SS, SV-B, EM, MF, TD, IC, and SM performed experiments and interpreted data. SS, NS, TD, MF, IC and SM conceived experiments. SM wrote the MS with the help of all authors. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
A signed consent form pertaining to genetic studies and the publication of scientific data was obtained.

Ethics approval and consent to participate
For gene studies, signed informed consent protocols were obtained from the parents. Ethics approval was from the Comité de Protection des Personnes d’Île-de-France 2 (CPP IDF2).

Author details
1INSERM U1149, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, Paris, France. 2Université Denis Diderot, Paris 7, Paris, France. 3Université Pierre et Marie Curie, Paris 6, Paris, France. 4Biochemical Genetics. Department, Human Genetics Division, National Research Center NRC, Cairo, Egypt. 5AP-HP, Hôpital Bichat-Claude Bernard, Biochimie, Paris, France. 6Département de Pédiatrie, AP-HP, Hôpital Necker-Enfants Malades, Paris, France. 7Département de Génétique & Centre de Référence Déficiences Intellectuelles de Causes Rares, Hôpital Pitié Salpêtrière, Paris, France. 8Groupe de Recherche Clinique « Déficience Intellectuelle et Autisme », UPMC, Paris, France. 9Neuropédiatrie, Hôpital Trousseau, Paris, France. 10Université Paris Descartes, Paris, France.

Received: 2 March 2016 Accepted: 15 June 2016

Published online: 24 June 2016

References
1. Jaeken J. Congenital disorders of glycosylation. Handb Clin Neurol. 2013;113:1737–43.
2. Aebi M, Hennet T. Congenital disorders of glycosylation: genetic model systems lead the way. Trends Cell Biol. 2001;11(3):136–41.
3. Buda P, Aebi M. The dolichol pathway of N-linked glycosylation. Biochim Biophys Acta. 1999;1426(2):239–57.
4. Harrison KD, Park EJ, Gao N, Kuo A, Rush JS, Waechter CJ, Lehrman MA, Sessa WC. Nogo-B receptor is necessary for cellular dolichol biosynthesis and protein N-glycosylation. Embo J. 2011;30(12):2490–500.
5. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy J, Bilas SL, Lehle L, Humbaur H, Adamowicz M, Szwieszewska E et al. SRD5A3 is required for converting polyenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010;142(2):203–17.
6. Kranz C, Jungeblut C, Denecke J, Erlekkotte A, Sohlich C, Debux V, Kehl HG, Harms E, Reiche A, Reichel S et al. A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy. Am J Hum Genet. 2007;80(3):433–40.
7. Lieu MT, Ng BG, Rush JS, Wood T, Basehore MJ, Hegde M, Chang RC, Abdelnour JE, Freeze HH, Wang YR. Severe, fatal multisystem manifestations in a patient with dolichol kinase-congenital disorder of glycosylation. Mol Genet Metab. 2013;110(4):484–9.
8. Grundahl JE, Guan Z, Rust S, Reunert J, Muller B, Du, Chesne I, Zerres K, Rudnik-Schoneborn S, Ortiz-Bruchle N, Hauser MG, et al. Life with too much polyenol: polyenol reductase deficiency. Mol Genet Metab. 2012;105(4):642–51.
9. Kasapkar CA, Tumer L, Ezgu FS, Hasangoğlu A, Race V, Matthijs G, Jaeken J. SRD5A3-CDCG: a patient with a novel mutation. Eur J Paediatr Neurol. 2012;16(5):554–6.
10. Park EJ, Grabinska KA, Guan Z, Stranevsky V, Hartmannova H, Hodanova K, Barosova V, Sovova J, Jozsef I, Onodruckova N, et al. Mutation of Nogo-B receptor, a subunit of cis-prenyltransferase, causes a congenital disorder of glycosylation. Cell Metab. 2014;20(3):448–57.
11. Zelinger L, Banin E, Obolensky A, Mizrahi-Meissonnier L, Beyozkin A, Bandah-Rozenfeld D, Frenkel S, Ben-Yosef T, Merin S, Schwartz SB, et al. A missense mutation in DHODH, encoding dehydrodolichol diphasate synthase, is associated with autosomal-reecessive retinitis pigmentosa in Ashkenazi Jews. Am J Hum Genet. 2011;88(2):207–15.
12. Zuchner S, Dallman J, Wen R, Beecham G, Naj A, Farooq A, Kohli MA, Whitehead PH, Hulme W, Konidari I, et al. Whole-exome sequencing links a variant in DHODH to retinitis pigmentosa. Am J Hum Genet. 2011;88(2):201–6.
13. Chantret I, Dupre T, Delenda C, Buccher S, Dancourt J, Barnier A, Charollais A, Heron D, Bader-Meunier S, Danco O, et al. Congenital disorders of glycosylation type Iq is defined by a deficiency in dolichyl-P-mannose: Man7GlcNAc2-PP-dolichol mannosyltransferase. J Biol Chem. 2002;277(28):25815–22.
14. Chantret I, Fasseu M, Zouak K, Le Bizec C, Sadou Yaye H, Dupre T, Moore SE. Identification of roles for peptide: Glycanase and endo-beta-N-acetylglucosaminidase (Engase1p) during protein N-glycosylation in human HepG2 cells. PLoS One. 2010;5(7), e11734.
15. Guimer A, Gabriel GC, Bajolle F, Tsang M, Liu H, Noll A, Schwartz M, El Malt R, Smith LD, Klena NT, et al. MMP21 is mutated in human heterozygosity and is required for normal left-right asymmetry in vertebrates. Nat Genet. 2015;47(11):1260–3.
16. Kanneggerisser C, Ronie R, Menard C, Reocreux M, Sfaello I, Barnier A, Dancourt J, Vuillaumier-Barrot S, de Baulny HO, Sfaello I, Barnier A, Charollais A, Heron D, Bader-Meunier S, Danco O, et al. Congenital disorders of glycosylation type Iq: five new patients and seven novel mutations. J Med Genet. 2010;47(11):729–35.
17. Dancourt J, Vuillaumier-Barrot S, de Baulny HO, Sfaello I, Barnier A, le Bizec C, Dupre T, Durand G, Seta N, Moore SE. A new intronic mutation in the DPM1 gene is associated with a milder form of CDG ie in two French siblings. Pediatr Res. 2006;59(6):835–9.
18. Crick DC, Sacco D, Rush JS, Frank DW, Krag SS, Waechter CJ. Induction of dolichyl-saccharide intermediate biosynthesis corresponds to increased long chain cis-isoprenyltransferase activity during the mitogenic response in mouse B cells. J Biol Chem. 1994;269(14):10559–85.
19. Rush JS, Gao N, Lehrman MA, Waechter CJ. Recycling of dolichyl monophosphate to the cytoplasmic leaflet of the endoplasmic reticulum after the cleavage of dolichyl pyrophosphate on the luminal monolayer. J Biol Chem. 2008;283(7):4987–93.
20. Mumberg D, Muller R, Funk M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene. 1995;156(1):119–22.
21. Chantret I, Dancourt J, Barbat A, Moore SE. Two proteins homologous to the N- and C-terminal domains of the bacterial glycosyltransferase M are required for the second step of dolichol-linked oligosaccharide synthesis in Saccharomyces cerevisiae. J Biol Chem. 2005;280(19):19236–42.
22. Seta N, Barnier A, Hochedez F, Besnard MA, Durand G. Diagnostic value of Western blotting in carbohydrate-deficient glycoprotein syndrome. Clin Chim Acta. 1996;254(2):131–40.
23. He P, Ng BG, Losfeld ME, Zhu W, Freeze HH. Identification of intercellular cell adhesion molecule 1 (ICAM-1) as a hypoglycosylation marker in...
congenital disorders of glycosylation cells. J Biol Chem. 2012;287(21):18210–7.
25. Lecca MR, Wagner U, Patrignani A, Berger EG, Hennet T. Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients. FASEB J. 2005;19(2):240–2.
26. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 1999;10(11):3787–99.
27. Haikarainen T, Krauss S, Lehtio L. Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients. FASEB J. 2005;19(2):240–2.
28. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 2012;287(22):18210–7.
29. Lam BL, Zuchner SL, Dallman J, Wen R, Alfonso EC, Vance JM, Pericak-Vance MA. Mutation K42E in dehydrodolichol diphosphate synthase (DHDDS) causes recessive retinitis pigmentosa. Adv Exp Med Biol. 2014;801:165–70.
30. Appelkvist EL, Kalen A. Biosynthesis of dolichol by rat liver peroxisomes. Eur J Biochem/FEBS. 1989;185(3):503–9.
31. Grunler J, Olsson JM, Dallner G. Estimation of dolichol and cholesterol synthesis in microsomes and peroxisomes isolated from rat liver. FEBS Lett. 1995;358(3):230–2.
32. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem. 2006;75:295–332.
33. Wardens RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem. 2006;75:295–332.
34. Schenk B, Imbach T, Frank CG, Grun brasman CE, Raymond GV, Hurvitz H, Kom-Lubetzki I, Reiß-Vik S, Haikarainen T, Krauss S, Lehtio L. Tankyrases: structure, function and therapeutic implications in cancer. Curr Pharm Des. 2014;20(41):6472–88.
35. Schenk B, Imbach T, Frank CG, Grunermann CE, Raymond GV, Hurvitz H, Kom-Lubetzki I, Reiß-Vik S, Haikarainen T, Krauss S, Lehtio L. Tankyrases: structure, function and therapeutic implications in cancer. Curr Pharm Des. 2014;20(41):6472–88.
36. Harrison KD, Miao RQ, Fernandez-Hernando C, Suarez Y, Davalos A, Sessa WC. Nogo-B receptor stabilizes N179P-102 type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab. 2009;10(3):208–18.
37. Harrison KD, Miao RQ, Fernandez-Hernando C, Suarez Y, Davalos A, Sessa WC. Nogo-B receptor stabilizes N179P-102 type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab. 2009;10(3):208–18.
38. Harrison KD, Miao RQ, Fernandez-Hernando C, Suarez Y, Davalos A, Sessa WC. Nogo-B receptor stabilizes N179P-102 type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab. 2009;10(3):208–18.
39. Harrison KD, Miao RQ, Fernandez-Hernando C, Suarez Y, Davalos A, Sessa WC. Nogo-B receptor stabilizes N179P-102 type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab. 2009;10(3):208–18.
40. Harrison KD, Miao RQ, Fernandez-Hernando C, Suarez Y, Davalos A, Sessa WC. Nogo-B receptor stabilizes N179P-102 type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab. 2009;10(3):208–18.